Syndax Pharmaceuticals Inc
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- 2 insiders sold shares within a monthSince Jun 1, 2026+1.6
Trials
- SNDXSyndax Pharmaceuticals2Calm
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Signing up patientsPhase 3468 patientsMain results: Jun 2029 - SNDXSyndax Pharmaceuticals2Calm
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Signing up patientsPhase 1/2447 patientsMain results: Dec 15, 2027
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
6 sales (2 not pre-planned) · 0 purchases
- Podlesak DennisBoard member · Oct 29, 2026Sold 8,000 sharesabout $114 thousand · pre-planned
- Metzger Michael AChief Executive Officer · Jul 8, 2026Sold 32,375 sharesabout $785 thousand · pre-planned
- Botwood Nicholas A.J.Head of R&D, CMO · Jun 12, 2026Sold 31,235 sharesabout $567 thousand · pre-planned
- Botwood Nicholas A.J.Head of R&D, CMO · Jun 11, 2026Sold 34,280 sharesabout $617 thousand · pre-planned
- Goldan Keith A.Chief Financial Officer · Jun 1, 2026Sold 1,177 sharesabout $22 thousand · not pre-planned
- Metzger Michael AChief Executive Officer · Jun 1, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.